Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 |
| NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | recruiting | Phase 1 | 134 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05230680 | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | recruiting | Phase 1 / Phase 2 | 41 | Won Seog KimOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06044506 | Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma | recruiting | Phase 1 | 3 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05768529 | Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05948033 | CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 | clinicaltrials |
| NCT05688488 | Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords | recruiting | Phase 1 / Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05842707 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 48 | Aibin Liang，MD，Ph.D.OTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04959903 | Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | recruiting | Phase 1 / Phase 2 | 36 | Smart Immune SASINDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682755 | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | recruiting | Phase 1 / Phase 2 | 77 | Sichuan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01638676 | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | recruiting | Phase 1 / Phase 2 | 55 | University of LouisvilleOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05043571 | CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | recruiting | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)(IbruOnOff) | recruiting | Phase 1 / Phase 2 | 50 | Jeanette LundinOTHER | 2 | Feb 25, 2021 | clinicaltrials |
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse(HOVON 136 NHL) | recruiting | Phase 1 / Phase 2 | 37 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | recruiting | Phase 1 / Phase 2 | 52 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04167696 | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02(CYCLE-1) | recruiting | Phase 1 | 27 | Celyad Oncology SAINDUSTRY | 2 | Jun 9, 2020 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02870244 | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | recruiting | Phase 1 | 18 | Loyola UniversityOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Nov 8, 2023source: clinicaltrials